Back to front
Section

Business

Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.

Latest

Amplia enters clinical collaboration with Eli Lilly to test narmafotinib plus Lilly’s KRAS G12C inhibitor olomorasib in non-small cell lung cancer

The companies said they signed a Clinical Trial Collaboration and Supply Agreement to evaluate Amplia’s investigational FAK inhibitor narmafotinib in combination with Eli Lilly’s investigational KRAS G12C therapy olomorasib (marketed as Lumakras in the U.S.), in patients with non-small cell lung cancer.

The Apex Times / Aug 4, 9:10 AM EDT / 1 min read
Read the brief
Amplia enters clinical collaboration with Eli Lilly to test narmafotinib plus Lilly’s KRAS G12C inhibitor olomorasib in non-small cell lung cancer
The Apex Times

THE APEX TIMES

More Stories

Leidos shares rise after second-quarter beat and higher full-year guidance
The Apex Times

THE APEX TIMES

Business / The Apex Times

Leidos shares rise after second-quarter beat and higher full-year guidance

Leidos Holdings (NYSE: LDOS) reported a second quarter that exceeded Wall Street expectations, leading the defense and technology contractor to lift its outlook for the full year, a move that drew investor attention on Tuesday.

Aug 4, 9:00 AM EDT
Spotify shares slide after second-quarter results miss expectations
The Apex Times

THE APEX TIMES

Business / The Apex Times

Spotify shares slide after second-quarter results miss expectations

Spotify Technology SA shares fell in pre-market trading after the music and podcast streaming company reported second-quarter 2026 results that missed Wall Street expectations, even as growth continued in its core businesses.

Aug 4, 9:00 AM EDT